Genprex Inc
GNPX
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
2776.4% upsideUndervalued by 2776.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.27 Million |
|---|---|
| Enterprise Value | $-16,777,235.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-17.4 |
| Beta | -0.93 |
| Outstanding Shares | 6,951,999 |
Return
| Return on Equity | -98.79% |
|---|---|
| Return on Assets | -82.37% |
| Return on Invested Capital | -3.09% |
Valuation & Multiples
| P/E Ratio | -0.32 |
|---|---|
| PEG | -2.58 |
| Price to Sales | - |
| Price to Book Ratio | 0.35 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 32.07 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.02%▲ 9.26% |
|---|---|
| Total Invested | $168,971▲ 1200.98% |
| Investors Holding | 26▲ 6.00% |
ESG Score
No data
About Genprex Inc
CEO: J. Rodney Varner Relevant Senate Committees
Provides critical non-partisan analysis and official 'revenue estimates' for all tax legislation, directly influencing corporate tax structures and policies that impact pharmaceutical companies' profitability and investment decisions.
Controls tax policy, which directly impacts corporate profitability, and influences entitlement spending (Medicare/Medicaid), which dictates a significant portion of pharmaceutical drug pricing and reimbursement.
Directly regulates the FDA, which is responsible for drug approval, manufacturing standards, and post-market surveillance, and the NIH, which funds critical biomedical research.
Has direct jurisdiction over intellectual property (patents), which is fundamental to pharmaceutical R&D, market exclusivity, and competition, and oversees antitrust enforcement impacting mergers.